Mithra Pharmaceuticals SA (MITRA.BR)

4.57 €

+0.26 (+6.03%)
Rating:
Recommendation:
-
Symbol MITRA.BR
Price 4.57 €
Beta 0.961
Volume Avg. 0.10M
Market Cap 247.387M
Shares () -
52 Week Range 4.26-22.1
1y Target Est -
DCF Unlevered MITRA.BR DCF ->
DCF Levered MITRA.BR LDCF ->
ROE -28.26% Sell
ROA -5.32% Neutral
Operating Margin -
Debt / Equity 1097.23% Strong Buy
P/E -1.70 Sell
P/B 4.78 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades


Mr. Francois Fornieri
Healthcare
Drug Manufacturers—Specialty & Generic
Brussels

Mithra Pharmaceuticals SA develops, manufactures, and markets complex therapeutics in the areas of contraception, menopause, and hormone-dependent cancers in Europe and internationally. Its development candidates include Estelle, which has completed phase III clinical trial, which is a combined oral contraceptive; Donesta, which is in phase III clinical trial for estetrol-based oral hormone treatment. The company also develops Myring, a contraceptive vaginal ring releasing a combination of hormones; Tibelia, a solution for treating menopause and osteoporosis; and Zoreline, a biodegradable subcutaneous implant for use in prostate and breast cancers, and benign gynecological indications. In addition, it offers NEXTSTELLIS, an oral contraceptive pill. In addition, the company provides products in polymeric forms, implants, sterile injectable products, and hormonal tablets. Mithra Pharmaceuticals SA was founded in 1999 and is headquartered in Liège, Belgium.